Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray.
International journal of psychiatry in clinical practice June 1, 2024 Ludovic Samalin, Lila Mekaoui, Pierre De Maricourt et al. 3 citations
An observational study of adults with treatment-resistant depression (TRD) treated with esketamine across three time periods found that patients had moderate-to-severe depression, with an average Montgomery-Åsberg Depression Rating Scale score of 32.6. The 157 treated patients (average age 49.0 years, 66.2% female) showed varied disease severity, subtypes, and comorbidities across cohorts. Later cohorts used esketamine earlier and before other treatments. The findings indicate a high burden of TRD and suggest esketamine is a potentially useful alternative, especially as clinicians gain more familiarity and access.